Finnish-based biotechnology company NADMED raised EUR 3.5 million (USD 3.9 million) in Series A funding led by Nordic Science Investments, with participation from Voima Ventures, University of Helsinki Funds, private European investors, and a grant from Business Finland.
The new funds will be used to expand NADMED's operations and development efforts for its nicotinamide adenine dinucleotide (NAD) measurement technology, enter the US and other international markets, and expand its operations and development efforts.
NADMED specializes in the development of blood testing technology for measuring NAD levels. Its proprietary method, developed from research at the University of Helsinki, is the first to measure all four bodily forms of NAD directly from fresh blood, providing rapid and accurate results. This breakthrough technology helps clinicians detect vitamin B3 deficiencies and offers more personalized treatments for age-related conditions such as metabolic disorders, cancer, and cardiovascular diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.